缺氧对非酒精性脂肪性肝病发病的影响*

doi:10.3969/j.issn.1672-5069.2016.02.034

摘要/Abstract

摘要： 非酒精性脂肪性肝病（NAFLD）患者存在系统性和肝脏局部缺氧。对于呼吸睡眠暂停综合征与脂肪性肝病的研究显示机体缺氧程度与胰岛素抵抗、肝脏脂肪变、炎症和纤维化程度相关。动物实验和分子生物学研究显示缺氧及其缺氧诱导因子能促进肝细胞脂肪堆积,加速肝脏炎症、纤维化,甚至肿瘤的发生和发展。

关键词: 非酒精性脂肪性肝病, 缺氧, 缺氧诱导因子

Abstract: Systematic and local hypoxia in liver is common in patients with nonalcoholic fatty liver diseases （NAFLD）. Studies on the relationship between obstructive sleep apnea and NAFLD show that the extent of hypoxia is positively correlated with insulin resistance,liver steatosis,and hepatic inflammation and fibrosis. Experiments in animals and molecular researches demonstrate that hypoxia and the hypoxia-inducible factors could promote the occurrence and progression of hepatic steatosis,inflammation,fibrosis,and even induce carcinoma in liver.

Key words: Nonalcoholic fatty liver disease, Hypoxia, Hypoxia-induced factor

管红雨(综述), 蔡晓波, 陆伦根(审校). 缺氧对非酒精性脂肪性肝病发病的影响^*[J]. 实用肝脏病杂志, 2016, 19(2): 237-240.

Guan Hongyu, Cai Xiaobo, Lu Lungen. Hypoxia in the pathogenesis of nonalcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 237-240.

参考文献

[1] Bhala N,Jouness RI,Bugianesi E.Epidemiology and natural history of patients with NAFLD. Curr Pharm Des,2013,19（29）:5169-5176.
[2] 范建高,曾民德.脂肪性肝病. 2版,北京：人民卫生出版社,2013:128-132.
[3] Savransky V,Nanayakkara A,Vivero A,et al. Chronic intermittent hypoxia predisposes to liver injury. Hepatology,2007,45（4）:1007-1013.
[4] Tanne F,Gagnadoux F,Chazouilleres O,et al. Chronic liver injury during obstructive sleep apnea. Hepatology,2005,41（6）:1290-1296.
[5] Lemoine M,Serfaty L.Chronic intermittent hypoxia:a breath of fresh air in the understanding of NAFLD pathogenesis. J Hepatol,2012,56（1）:20-22.
[6] Nath B,Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology,2012,55（2）:622-633.
[7] Broughan TA,Naukam R,Tan C,et al. Effects of hepatic zonaloxygen levels on hepatocyte stress responses. J Surg Res,2008,145:150-160.
[8] Mantena SK,Vaughn DP,Andringa KK,et al. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J,2009,417（1）:183-193.
[9] Burgueo AL,Gianotti TF,Mansilla NG,et al. Cardiovascular disease is associated with high-fat-diet-induced liver damage and up-regulation of the hepatic expression of hypoxia-inducible factor 1α in a rat model.Clin Sci（Lond）,2013,124（1）:53-63.
[10] Polotsky VY,Patil SP,Savransky V,et al. Obstructive sleep apnea,insulin resistance,and steatohepatitis in severe obesity. Am J Respir Crit Care Med,2009,179（3）:228-234.
[11] Li J,Grigoryev DN,Ye SQ,et al. Chronicintermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J Appl Physiol,2005,99（5）:1643-1648.
[12] Savransky V,Bevans S,Nanayakkara A,et al. Chronicintermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol,2007,293（4）:871-877.
[13] Aron-Wisnewsky J,Minville C,Tordjman J,et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol,2012,56（1）:225-233.
[14] Sookoian S,Pirola CJ. Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes:a meta-analysis.Obes Surg,2013,23（11）:1815-1825.
[15] Bostrom P,Magnusson B,Svensson PA,et al. Hypoxia converts human macrophages into triglyceride-loaded foam cells. Arterioscler Thromb Vasc Biol,2006,26（8）:1871-1876.
[16] Wada T,Shimba S,Tezuka M. Transcriptional regulation of the hypoxia inducible factor-2alpha （HIF-2alpha） gene during adipose differentiation in 3T3-L1 cells. Biol Pharmaceut Bull, 2006,29（1）:49-54.
[17] Belanger A,Luo Z,Vincent K,et al. Hypoxia-inducible factor 1 mediates hypoxia-induced cardiomyocyte lipid accumulation by reducing the DNA binding activity of peroxisome proliferator-activated receptor alpha/retinoid X receptor. Biochem Biophy Res Commun,2007,364（3）:567-572.
[18] Nath B,Levin I,Csak T,et al. Hepatocyte-specific hypoxia-inducible factor-1α is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice.Hepatology, 2011,53（5）:1526-1537.
[19] Rankin EB,Rha J,Selak MA,et al. HIF-2 regulates hepatic lipid metabolism. Mol Cell Biol,2009,29（16）:4527-4538.
[20] Kucejova B,Sunny NE,Nguyen AD,et al. Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death. Oncogene,2011,30（18）:2147-2160.
[21] Kim WY,Safran M,Buckley MR,et al. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J,2006,25（19）:4650-4662.
[22] Nishiyama Y,Goda N,Kanai M,et al. HIF-1α induction suppresses excessive lipid accumulation in alcoholic fatty liver in mice. J Hepatol,2012,56（2）:441-447.
[23] Carabelli J,Burgueo AL,Rosselli MS,et al. High fat diet-induced liver steatosispromotes an increase in liver mitochondrial biogenesis in response to hypoxia. J Cell Mol Med,2011,15（6）:1329-1338.
[24] Koumenis C,Naczki C,Koritzinsky M,et al. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor HIF2alpha. Mol Cell Biol,2002,22（21）:7405-7416.
[25] Chalasani N,Gorski CJ,Asghar MS,et al. Hepatic cytochrome P450 2E1 activity in non-diabetic patients with nonalcoholic steatohepatitis. Hepatology,2003,37（3）:544-550.
[26] Peyssonnaux C,Cejudo-Martin P,Doedens A,et al. Cutting edge: Essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. J Immunol, 2007,178（12）:7516-7519.
[27] Scharte M,Han X,Uchiyama T,et al. LPS increases hepatic HIF-1alpha protein and expression of the HIF-1-dependent gene aldolase A in rats. J Surg Res,2006,135（2）:262-267.
[28] Blouin CC,Page EL,Soucy GM,et al. Hypoxic gene activation by lipopolysaccharide inmacrophages:implication of hypoxia-inducible factor 1alpha. Blood,2004,103（3）:1124-1130.
[29] Qu A,Taylor M,Xue X,et al. Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation,inflammation,and fibrosis.Hepatology,2011,54（2）:472-483.
[30] Nakamura K,Zen Y,Sato Y,et al. Vascular endothelial growth factor,its receptor Flk-1,and hypoxia inducible factor-1alpha are involved in malignant transformation in dysplastic nodules of the liver. Hum Pathol,2007,38（10）:1532-1546.
[31] Moon J,Welch T,Gonzalez F,et al. Reduced liver fibrosis in hypoxia-induciblefactor-1{alpha}-deficient mice. Am J Physiol, 2009,296（3）:582-592.
[32] Corpechot C,Barbu V,Wendum D,et al. Hypoxiainduced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology,2002,35（5）:1010-1021.
[33] Shi YF,Fong CC,Zhang Q,et al. Hypoxia induces theactivation of human hepatic stellate cells LX-2 through TGF-beta signaling pathway. FEBS Lett,2007,581（2）:203-210.
[34] Desmet VJ. Ductal plates in hepatic ductular reactions. Hypothesis and implications. I. Types of ductular reaction reconsidered.Virch Arch,2011,458（3）:251-259.
[35] Corpechot C,Barbu V,Wendum D,et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology, 2002,35（5）:1010-1021.
[36] Novo E,Cannito S,Zamara E,et al. Proangiogenic cytokines as hypoxiadependentfactors stimulating migration of human hepatic stellate cells. Am J Pathol,2007,170（6）:1942-1953.
[37] Rosmorduc O,Housset C.Hypoxia:a link between fibrogenesis, angiogenesis,and carcinogenesis in liver disease. Semin Liver Dis,2010,30（3）:258-270.
[38] Wong CC,Kai AK,Ng IO.The impact of hypoxia in hepatocellular carcinoma metastasis.Front Med,2014,8（1）:33-41.

缺氧对非酒精性脂肪性肝病发病的影响^*

Hypoxia in the pathogenesis of nonalcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[3]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[4]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[5]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[6]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[7]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[8]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[9]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[10]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[11]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[12]	张枫, 阎妍. 非酒精性脂肪性肝病患者血清载脂蛋白B水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 61-64.
[13]	宋娜, 刘晓燕, 刘畅, 山秀杰, 苏东峰, 李丽慧. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(1): 65-68.
[14]	崔清华, 陶红, 王晓玥, 张凤丽. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平和心功能指标的变化研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 69-72.
[15]	钟燕, 苏淑婷综述, 宓余强审校. 非酒精性脂肪性肝病治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(1): 145-148.